NETs: Capecitabine plus temozolomide gives longer PFS than temozolomide alone
Dr Pamela Kunz speaks to ecancer about a randomised study, known as E2211, of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumours.
She continues by outlining the methodology of the study.
Dr Kunz then summarises the key findings which showed the longest PFS and highest RR reported for advanced pancreatic neuroendocrine tumours
Видео NETs: Capecitabine plus temozolomide gives longer PFS than temozolomide alone канала ecancer
She continues by outlining the methodology of the study.
Dr Kunz then summarises the key findings which showed the longest PFS and highest RR reported for advanced pancreatic neuroendocrine tumours
Видео NETs: Capecitabine plus temozolomide gives longer PFS than temozolomide alone канала ecancer
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metas...
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC
Breast cancer prevention in high-risk post-menopausal women
Regional lymph node irradiation in early breast cancer
Latest advances in mHSPC from ASCO GU 2020
ESMO 2017: Prostate cancer highlights
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans
Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant br...
Breast cancer highlights from ASCO 2019
The CAR T cell revolution in cancer therapy
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients
CLL14: Venetoclax plus obinutuzumab in untreated CLL
Prostate cancer patients receiving androgen-deprivation therapies shown to be at lower risk from...
Managing the side effects of CAR T-cell therapy
LUMINA results: Women with low levels of the Ki67 biomarker can avoid outcomes related to RT
Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive disea...
Maintenance chemotherapy extends life for children with rare rhabdomyosarcoma
Advances in prostate cancer in the last 10 years and a glimpse to the future
Holistic management of patients with ALK-positive NSCLC
Master pathways and targets in T cell acute lymphoblastic leukaemia
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts